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Eﬀ ect of quercetin on the transport of ritonavir to the central 
nervous system in vitro and in vivo
The aim of this study was to identify an eﬀ ective fl avonoid 
that could improve the intracellular accumulation of rito-
navir in human brain-microvascular endothelial cells (HB-
MECs). An in vivo experiment on Sprague-Dawley rats was 
then designed to further determine the fl avonoid’s impact 
on the pharmacokinetics and tissue distribution of ritona-
vir. In the accumulation assay, the intracellular leve l of rito-
navir was increased in the presence of 25 mmol L–1 of fl avo-
noids in HBMECs. Quercetin showed the strongest eﬀ ect 
by improving the intracellular accumulation of ritonavir by 
76.9 %. In the pharmacokinetic study, the presence of quer-
cetin in the co-administration group and in the pretreat-
ment group signifi cantly decreased  the area under the 
plasma concentration-time curve (AUC0–t) of ritonavir by 
42.2 % (p < 0.05) and 53.5 % (p < 0.01), and decreased the peak 
plasma concentration (cmax) of ritonavir by 23.1 % (p < 0.05) 
and 45.8 % (p < 0.01), respectively, compared to the control 
group (ritonavir alone). In the tissue distribution study, the 
ritonavir concentration in the brain was signifi cantly in-
creased 2-fold (p < 0.01), during the absorption phase (1 h) 
and was still signifi cantly higher (p < 0.05) during the dis-
tribution phase (6 h) in the presence of quercetin.
Keywords: q uercetin, fl avonoids, ritonavir, blood-brain bar-
rier, pharmacokinetics
 Although highly active antiretroviral therapy (HAART) has greatly promoted the 
clinical treatment of HIV-1 infection, unresolved issues still remain. For instance, despite 
the fact that the blood viral load can be successfully reduced by HAART, the brain has 
proven to be a sanctuary site where the virus can reside relatively un-interrupted by ther-
apeutic intervention (1–4). Thus, despite undetectable plasma viral RNA levels, low-level 
active replication of the virus is still present in the central nervous system (CNS), which 
can result in AIDS-related neurological complications (5). One of the strategies through 
which HIV-1 can reduce HAART eﬃ  cacy in the brain is to rely on the presence of drug-
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eﬄ  ux transporters in the blood-brain barrier (BBB), which include members of the ATP- 
-binding cassett e superfamily of proteins, such as P-glycoprotein (P-gp), multidrug resis-
tance-associated protein (MRP), and breast cancer resistance protein (BCRP) (6). The 
HIV-1 pro tease inhibitors (HPIs) are key components of the HAART currently used to treat 
HIV-1 infection. A strong body of evidence  suggests that HPIs are substrates of P-gp and, as 
a result, the limited ability of these drugs to transverse the BBB is att ributed to the activity 
of this eﬄ  ux transporter (7–11). A recent study showed that MDR1 specifi c drug-eﬄ  ux 
function increases in BBB following co-exposure to HIV-1 and HPIs, which can reduce the 
penetration of HPIs into the infected brain reservoirs of HIV-1 (12).
To overcome tumor cell resistence caused by the over-expression of P-gp, a chemosen-
sitizer is used to inhibit the eﬄ  ux pump activity (13, 14). In principle, a similar strategy 
could be employed for HPIs therapy in order to enhance their distribution into sites such 
as the brain. Compounds such as verapamil, quinidine, and cyclosporin A have shown 
inhibitory eﬀ ects on P-gp function. However, these compounds have an intrinsic toxicity 
due to their pharmacological activity and cannot be used safely at dosages required for the 
inhibition of drug eﬄ  ux in vivo. Although some competitive inhi bit or s of P-gp are being 
tested as an approach to increase HPIs levels within the brain, their g eneralized inhibition 
has not been a safe or feasible approach since other organs also suﬀ er from toxic xenobio-
tics (15). The search for chemosensitizers, which have the advantage of being eﬀ ective in-
hibitors without side-eﬀ ects, has focused on plant-derived fl av onoids (16). Flavonoids are 
constituents of fruits, vegetables, herbal dietary supplements, as well as components of 
traditional Chinese m edicines, and several fl avonoids have been proven to modulate the 
function and expression of P-gp (17–19). 
This study was designed to seek a safe and eﬀ ective fl avonoid to be used as an agent 
to increase HPIs levels within the brain, and to determine whether the result of fl avonoids 




Ritonavir was purchased from Xiamen Henry Biochem Co., Ltd. (China). Saquinavir 
(an internal standard for high performance liquid chromato graphy-tandem mass chroma-
togra phy, HPLC-MS/MS, analysis of ritonavir) with a purity > 99% was from United States 
Pharmacopoeia USA). Epicatechin gallate (ECG), hesperetin, kaempferol, quercetin, iso-
q uercetrin, morinhydrate, chrysin and epicatechin (EC) (purity ≥ 99 %) were purchased 
from Nantong Feiyu Biological Technology Co., Ltd. (China). Verapamil was obtained from 
the China National Institute for Food and Drug Control (China). HPLC-grade methanol, 
acetonitrile, methyl tert-butyl ether, sodium tetraborate, ammonium formate and formic 
acid were purchased from Fisher Scientifi c Co. (USA). Bicinchoninic acid (BCA) protein 
assay kit and bov ine serum albumin (BSA) were purchased from  Tiangen Biotech (China). 
Distilled water was purifi ed by a Derect-Q® Ultrapure Water System (Millipore, USA). The 
mobile phase used in HPLC-MS/MS was fi ltered using a 0.45-μm membrane fi lter, and was 
supplied by Ameritech Co. (USA).
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Sprague-Dawley rats (6–10 weeks old, half male and half f emale, 250–300 g) were 
purchased from the Academy of Military Medical Sciences (Beĳ ing, China) and raised in 
the animal room of the Peking University People’s Hospital (Beĳ ing, China), under a 12-h 
light-dark cycle. The animals were housed with free access to laboratory food and water 
ad libitum. Exp erimental procedures were reviewed and approved by the Ethics Committ ee 
of the Peking University People’s Hospital, and were designed in accordance with the 
“Guide for the Care and Use of Laboratory Animals”.
Cell culturing
Hum an brain-microvascular endothelial cells (HBMECs) were obtained from the Cell 
Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). 
HBMECs were incubated at 37 °C and in the presence of 5 % CO2 in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented by 10 % heat-inactivated fetal bovine serum, 
antibiotics (penicillin 100 U mL–1, streptomycin 100 μg mL–1), and 2 mmol L –1 L-glutamine (all 
from Gibco/BRL, Germany). HBMECs whose monlayers reached confl uence were selected 
and the old media were discarded. The cells were washed twice with phosphate-buﬀ ered 
saline (PBS) at 37 °C. A 0.25 % trypsin-EDTA solution was then added to the cells at about 0.12 
mL cm–2. Aft er incubation at 37 °C for 15 min, the solution was discarded and new culture 
medium was added. The cells att ached to  the wall were gently fl uctuated with the medium 
using a transfer pipett e until the cells were detached and suspended. The cell density was 
adjusted to approximately 5 × 104 mL–1, and the cells were inoculated in a new culture fl ask. 
The medium was replaced every other day for regular cellular metabolism and the cells were 
subcultured approximately every three days in order to maintain proper cell density.
Intracellular accumulation of riton avir
Accumulation of ritonavir in HBMECs was examined in confl uent cell cultures as previ-
ously described (20, 21). HBMECs were seeded into a 6-well plate, at 2 × 104 cells per well. When 
cells were 70–80 % confl uent, aft er the addition of 50 μmol L–1 of ritonavir, either 25 μmol L–1 
of various fl avonoids or 100 μmol L–1 verapamil (the  drugs were dissolved in solvent with 
less than 1 % of the RPMI 1640 by volume was added, except for the blank control. Cells were 
then incubated for another 4 hours in a CO2 incubator to reach a steady-state level. The cells 
were then rinsed ten times with the ice-cold PBS in a culture dish to remove the drugs on the 
cell surface. Aft er the addition of 500 μL of de-ionized water, the cells were transferred into a 
micro centrifuge tube with a cell scraper. The culture dish and cell scraper were rinsed with 
500 μL of de-ionized water and the suspension was then transferred into micro centrifuge 
tube. The cell suspension was processed with an ultrasonic cell disruption system 40 times 
(working frequency 10, disruption 3 s, interval 3 s). The lysate solution was centrifuged for 
5 min at 13400 rpm, and the supernatant was kept at –20 °C until HPLC-MS/MS analysis.
 Pharmacokinetic study
For the phar maco kinetic study, eighteen Sprague-Dawley rats were randomly divided 
into three groups (n = 6, half male and half female). The rats in the control group were 
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orally administered ritonavir at a dose of 20 mg kg–1 bm aft er being orally administered a 
blank solvent for 7 consecutive days. The rats of co-administration group were orally co-
admini stered ritonavir at a dose of 20 mg kg–1 and quercetin at a dose of 100 mg kg–1 bm, 
aft er being orally administered a blank solvent for 7 consecutive days. The rats of pretreat-
ment group were orally administered ritonavir at a dose of 20 mg kg–1 with quercetin at a 
dose of 100 mg kg–1, aft er being orally pretreated with 100 mg kg–1 quercetin for 7 consecu-
tive days. The rats were fasted for 12 hours prior to the beginning of experiments (on the 
eighth day) and had free access to sterilized water.
Aft er oral admin istration blood samples (200 μL) were collected into heparinized cen-
trifuge tubes a t predetermined time intervals of 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 hours 
from the retro orbital vein using heparinized capillary tubes. Control blood samples were 
obtained before dosing. Blood samples were immediately centrifuged for 5 min at 12,000 
rpm, and a 100-μL aliquot of plasma was stored in a freezer at –20 °C until HPLC-MS/MS 
analysis.
Tissue distribution  study 
For the tissue distribution study, 36 Sprague-Dawley rats were randomly divided into 
2 groups (n = 18, half male and half female). The rats were fasted for 12 h prior to the begin-
ning of experiments and had free access to sterilized water. The rats were orally given a 
dose of 20 mg kg–1 of ritonavir with or without quercetin (100 mg kg–1). For the control, a 
blank solvent was given in comparable amounts (5 mL kg–1). At each of the time points (1, 
6 and 12 h) following dosing, six rats were sacrifi ced and brain, liver and kidney tissues 
were collected. Tissue samples were rinsed with physiological saline to remove blood or 
content, weighed, blott ed on filter paper, and then stored in a freezer at –20 °C until HPLC-
MS/MS analysis.
HPLC-MS/MS quantitative analysis of ritonavir
Conditions. – High performance liquid chr omatography was performed using an Agilent 
1200 HPLC system consisting of a G1312A binary pump, a G1379B degasser, a G1329A autos-
ampler and a G1316A column oven (Agilent, USA).  Ritonavir was separated on a Resteck 
Ultra C18 column (150 × 2.1 mm i.d., 5.0 μm, USA) maintained at 20 ± 0.5 °C (amb ient tem-
perature of the la boratory). The mixed mobile phase delivered at 300 μL min–1 was CH3CN/
H2O, 67.75:22.25 (V/V), con taining 0.2 mmol L–1 NH4COOH in CH3CN and H2O. The retention 
times of ritonavir and the internal standard in plasma samples were approximately 2.5 and 
3.3 min, respectively. Detection was carried out on an API Qtrap 5500 MS/MS system (Ap-
plied Biosystems, USA) equipped with an electrospray interface (ESI) and operated in the 
positive ionization mode. Multiple-reaction monitoring (MRM) at unit resolution was em-
ployed to monitor the transitions of molecular ions ([M-H]) of ritonavir at m/z 721.4 296.2 
and that of the internal standard at m/z 671.4 570.4. Optimized MS parameters were: cur-
tain gas, gas 1 (nitrogen), and gas 2 (nitrogen) 206.85, 275.8 and 275.8 kPa, respectively, dwell 
time 200 ms, ionspray voltage +4500 V, ion source temperature 500 °C, declustering potential 
(DP) 0 V for ritonavir, and 0 V for the internal standard; collision energy (CE) –26 V for rito-
navir and –46 V for the internal standard (volt is a standard unit of parameters in the instru-
ment). Data acquisition and analysis were performed using the analyst soft ware version 1.5.1 
(Applied Biosystems, Foster City, CA, USA).
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Ritonavir in HBMECs. – The intracellular concentration of ritonavir in HBMECs was 
determined by HPLC-MS/MS. No eﬀ ect on cell viability was observed at these concentra-
tions during the incubation period (data not shown). Results were normalized to the pro-
tein content of cells in each well (22, 23). The protein content in the lysate solution of cells 
was determined using the commercially available BCA protein assay. The acc umulation 
of ritonavir was expressed as uptake per mg protein of the cells relative to the drug con-
centration (ng kg–1 protein).
Ritonavir in blood plasma. – Rit onavir in plasma was determined aft er the following 
treatment. Prior to the determination, 200 μL of IS (saquinavir) working solution (20 ng mL–1), 
500 μL of sodium tetraborate (0.1 mmol L–1) and 3 mL methyl tert-butyl ether were added 
to a 10-μL aliquot of plasma in a 7-mL Eppendorf tube. The mixture was vortex-mixed for 
10 min and centrifuged at 4000 rpm for 5 min. The upper layer (2.8 mL) was carefully 
transferred to another 7-mL clean Eppendorf tube and evaporated at 40 °C under a gentle 
stream of nitrogen. The dry residue was then reconstituted with the 400 μL of mobile 
phase and vortex-mixed for 3 min. Finally, a 10 μL of the solution was injected into the 
HPLC-MS/MS system. 
Ritonavir in tissues. – For determination of ritonavir in a tissue, each weighed tissue 
sample was thawed and then homogenized in ice-cold physiological saline (1:10, m/V). The 
tissue homogenate was then taken and processed further like plasma samples. Finally, 10 μL 
of each sample solution was analyzed by HPLC-MS/MS system. 
Pharmacokinetics 
The pharmacokinetic parameters of ritonavir wer e analyzed by non-compartmental 
analysis using the PK-Solver Program (version 2.0, China Medicinal University, Nanjing, 
China). The elimination rate constant (Kel) was calculated by log-linear regression of rito-
navir concentration data during the elimination phase, and the terminal half-life (t1/2) was 
calculated as 0.693/Kel. The peak concentration (cmax) of ritonavir in plasma as well as the 
time to reach cmax (tmax), were obtained by visual inspection of the data from the concentra-
tion-time curve. The area under the plasma concentration-time curve (AUC) from time 
zero to the time of the last measured concentration (clast) was calculated by means of the 
linear trapezoidal rule. AUC0–∞ was determined by adding AUC0–t, and the extrapolated 
area was determined by calculating clast/Kel. Mean residence time (MRT) was the estimated 
time for 63.2 % of the administered dose to be eliminated. The total body clearance of oral 
(Cl/F, here F represents the bioavailability of ritonavir) ritonavir was calculated from the 
quotient of the dose and the AUC0–∞.
Data analysis
All analyses were performed using SPSS (SPSS 11.0, SPSS, Inc., Chicago, USA). For 
comparisons of the mean values between two experimental groups,  Student’s unpaired 
t-test was used. Comparisons between three or more experimental groups were performed 
using a one-way analysis of variance, followed by Dunnett ’s test. Diﬀ erences were conside-
red statistically signifi cant when p < 0.05.
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The method was checked according to the guidelines for bioanalytical method validation. 
The calibration curve for ritonavir was linear over the concentration range 0.1–100 ng mL–1, 
which were found to be adequate for the analysis of the lysate solution of cells, plasma and 
tissues. The quantitation limit, with a coeﬃ  cient of variation of less than 20 %, was 0.1 ng 
mL–1. Inter- and intra-day coeﬃ  cients of variation for the low, middle, and high quality 
control samples were less than 15 %. Ritonavir was found stable when kept at 25 °C for 24 h, 
at –20 °C for 30 days, and aft er 3 freeze-thaw cycles.
Eﬀ ect of fl avonoids on intracellular accumulatio n of ritonavir in HBMECs
In the accumulation assay, the intracellular level of ritonavir in HBMECs was mea-
sured aft er 4 h of incubation with various fl avonoids (Fig. 1). The positive control vera-
pamil at 100 μmol L–1 signifi cantly increased (p < 0.01) the intracellular accumulation of 
ritonavir by 133.2 % compared to the control (ritonavir alone). Among the eight fl avonoids, 
hesperetin, quercetin, isoquercetin and EC demonstrated signifi cant eﬀ ects on the accu-
mulation of ritonavir in HBMECs,  with quercetin showing the strongest eﬀ ect, with an 
increase of 76.9 %. In other words, the results  indicated that quercetin had the highest 
potential for inhibiting P-gp, the important eﬄ  ux transporter in the cell membrane. 
Fig. 1. Eﬀ ects of 25 μmol L–1 fl avonoids and 100 μmol L–1 verapamil on the accumulation of ritonavir in 
HBMECs. Data are represented as mean ± SD (n = 3). * p < 0.05, and ** p < 0. 01 compared to the control.
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Eﬀ ect of quercetin on pharmacokinetics of orally administered ritonavir
The mean arterial plasma concentration-time profi les of ritonavir following oral ad-
ministration in the presence or absence of quercetin are illustrated in Fig. 2 and the phar-
macokinetic parameters of ritonavir are summarized in Table I. Compared to the control 
group (ritonavir alone), the presence of quercetin in the co-administration group and the 
pretreatment gro up signifi cantly decreased AUC0–t of ritonavir by 42.2 % (p < 0.05) and 53.5 % 
(p < 0.01), and markedly decreased the peak plasma concentration (cmax) of ritonavir by 23.1 % 
(p < 0.05) and 45.8 % (p < 0.01), respectively. The time to reach maximum plasma concentra-
tion (tmax) was postponed and the Cl/F of ritonavir was increased in the presence of quer-
cetin. In addition, no signifi cant changes in t1/2 and MRT of ritonavir were found aft er 
quercetin co-administration either the co-administration group or the pretreatment group.
Eﬀ ect of quercetin on tissue distribution of orally administered ritonavir
The tissue distribution results of orally administered ritonavir in the absence or pres-
ence of quercetin are shown in Table II. The ritonavir concentration in the brain was mark-
edly increased (p < 0.01), by 205.3 %, during the absorption phase (1 h), and was still sig-
nifi cantly higher (p < 0.05) than the contro l during the distribution phase (6 h) when 
Fig. 2. Mean plasma concentration-time profi les of ritonavir in  rats. (●) Mean plasma concentration-time 
profi les of ritonavir in the control group rats, which were orally administered ritonavir (20 mg kg–1 bm) 
aft er being administered orally blank solvent for 7 consecutive days; () mean plasma concentration-
time profi les of ritonavir in the co-administration group, which were orally co-administered ritonavir 
(20 mg kg–1 bm) with quercetin (100 mg kg–1 bm), aft er being orally administered blank solvent for 7 
consecutive days; () mean plasma concentration-time profi les of ritonavir in the pretreatment group 
rats which were orally co-administered ritonavir (20 mg kg–1 bm) with quercetin (100 mg kg–1 bm) aft er 
being orally pretreated with quercetin (100 mg kg–1 bm) for 7 consecutive days. Data are represented as 
mean ± SD (n = 6). Insert: enlarged portion of up to 6 hours.
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AUC 0–t (ng h mL–1) 20072.74 ± 8268.43 11593.15 ± 3567.15c 9329.95 ± 3668.79d 
cmax (ng mL–1) 1490.00 ±281.50 1145.67 ± 222.37c 807.60 ± 221.79d 
tmax (h) 1.20 ± 0.27 3.83 ± 1.96d 2.60 ± 1.13c 
t1/2 (h) 3.54 ± 1.14 2.88 ± 1.47 4.90 ± 2.15 
MRT (h) 9.25 ± 4.29 7.62 ± 1.29  9.11 ± 2.34
Cl/F (L mg–1 h–1) 0.00148 ± 0.00070 0.00187 ± 0.00063 0.00283 ± 0.00124c 
Data are represented as mean ± SD (n = 6). 
a 20 mg kg–1 bm.
b 100 mg kg–1 bm.
c p < 0.05, d p < 0. 01 compared to the control. 
AUC0–t – area under the plasma concentration-time curve from time zero to the time of last measured concentra-
tion, cmax – peak concentration; tmax – time to reach peak concentration, t1/2 – terminal half-life, MRT, mean residence 
time, Cl/F – total body clearance, F – bioavailability.
Table II. Distribution of ritonavir in the brain, liver and kidney aft er its oral administration in the absence 


















  1 135.34 ± 46.40 413.23 ± 190.90b 97166.61 ± 12084.66 90346.67 ± 15751.75 16976.67 ± 5680.02 19580.00 ± 5040.83
  6 95.33 ± 24.41 129.87 ± 28.74a 40773.33 ± 12362.32 70253.33 ± 16920.70b 15979.32 ± 6853.40 12809.87 ± 5521.29
12 56.43 ± 21.35 54.41 ± 16.20 36102.09 ± 16824.33 34980.00 ± 12815.24 14080.00 ± 1442.64 8107.09 ± 2826.15b
Data are represented as mean ± SD (n = 6). Ritonavir dose 20 mg kg–1; quercetin dose 100 mg kg–1.
a p < 0.05, and b p < 0. 01 compared to the control.
co-administrated with quercetin. There were no signifi cant changes for ritonavir concen-
tration in the brain in the elimination phase (12 h), with or without quercetin. Ritonavir 
concentration in the liver was signifi cantly increased (p < 0.01), by 72.3 %, during the distri-
bution phase (6 h), and showed no signifi cant change in the absorption phase (1 h) or 
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elimination phase either (12 h). However, the ritonavir concentration in the kidney tissue 
decreased markedly (p < 0.01), by 42.4 %, during the elimination phase (12 h) but had no 
signifi cant changes either during the absorption (1 h) or distribution phase (6 h).
It can be seen that there was a wide changing range of SD within the parameters in 
Table II. One reason is that all the analyses were based on the data of 6 experimental ani-
mals in each group, which could be considered as a small sample size. Other reasons are 
still to be explored. K. Berginc et al. (24) investigated the impact of garlic fl avonoids on the 
hepatic pharmacokinetics of saquinavir and darunavir. It was very confusing that aged 
garlic extract signifi cantly inhibited saquinavir eﬄ  ux from rat hepatocytes, while the ef-
fl ux of darunavir signifi cantly increased. The authors inferred that the competition be-
tween saquinavir and garlic constituent(s) for the same binding site on the eﬄ  ux trans-
porter and the positive cooperative eﬀ ect between darunavir and garlic phytochemical(s), 
which bind to separate binding places on the transporter, are the most probable mecha-
nisms. In our study, ritonavir was used as the test drug, whose chemical structure is dif-
ferent from saquinavir and darunavir, so the exact mechanism is still unclear. We must 
admit that the current manuscript is just a primary exploratory study and our group will 
consistently investigate the detailed mechanism in the future.
Summary of the study
In this study, we assessed the eﬀ ects of eight fl avonoids on the accumulation of ritonavir 
in HBMECs and found that quercetin was the most eﬀ ective in improving the intracellular 
concentration of ritonavir. Further, the in vivo experiment sought to determine if quercetin 
could serve as an agent to improve the brain concentration of ritonavir in rats. Based on the 
results of animal experiments, we found that quercetin had a signifi cant eﬀ ect on the phar-
macokinetics of ritonavir in rats. Aft er co-administration with quercetin, the postponed tmax 
in rats demonstrated tha t the absorption of ritonavir was slowed down. The AUC0–t and cmax 
were decreased, which indicated that the amount of ritonavir exposed in plasma was re-
duced. However, the concentration of ritonavir in the brain increased signifi cantly when 
orally co-administrated with quercetin. The results of tissue studies were consistent with 
the results of the intracellular accumulation assay of ritonavir in HBMECs. Many reports 
indicate that fl avonoids modulate the cell multi-drug resistance mediated by P-gp (25–27), 
which plays a role in the barrier function of BBB. As ritonavir is a substrate of P-gp, modulat-
ing P-gp might be a mechanism that could improve the concentration of ritonavir in the 
brain. Quercetin, which has a consistent eﬀ ect on the modulation of ritonavir in vitro and in 
vivo, might become a safe and eﬀ ective agent for increasing HP Is levels within the brain.
CONCLUSIONS
This study found that quercetin screened from the in vitro experiment had a signifi -
cant eﬀ ect on the pharmacokinetics of ritonavir in rat s and could markedly enhance the 
distribution of ritonavir into the brain in vivo. These fi ndings suggest a new strategy that 
might result in higher brain distributions reduced toxicity, and improved eﬃ  cacy of HPIs 
by using a plant-derived fl avonoid as a chemosensitizer.
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